MYC-rearranged lymphomas other than Burkitt: Comparison between R-CHOP and Burkitt-type immunochemotherapy

Med Clin (Barc). 2017 Oct 23;149(8):339-342. doi: 10.1016/j.medcli.2017.03.056. Epub 2017 Jun 23.
[Article in English, Spanish]

Abstract

Background and objective: MYC-rearranged (MYC-R) lymphomas other than Burkitt lymphoma (BL) are very aggressive, with poor prognosis when treated with standard regimens. We aimed to study the characteristics and outcome of a series of MYC-R lymphomas comparing the treatment results between R-CHOP based and a specific intensive regimen for BL (BURKIMAB).

Patients and methods: Retrospective study of patients diagnosed with MYC-R. Translocations of MYC, BCL2 and BCL6 were evaluated by fluorescent in situ hybridization. Patients were treated with either, R-CHOP based immunochemotherapy or the Burkitt type regimen, BURKIMAB.

Results: Thirty-four MYC-R lymphoma cases were studied: 21 treated with R-CHOP and 13 treated with BURKIMAB. There were no differences in CR rate; 45% (9/20) for R-CHOP and 42% (5/12) for BURKIMAB (P=.99). Although overall survival (OS) and progression free survival (PFS) of BURKIMAB-treated patients were better than those of R-CHOP-treated (3y-OS: 46 vs. 24%; 3y-PFS: 46 vs. 10%), the differences were not statistically significant.

Conclusion: MYC-R lymphomas show poor outcomes even when treated with intensive immunochemotherapy for BL.

Keywords: Immunochemotherapy; Inmunoquimioterapia; Linfoma; Lymphoma; MYC; Prognosis; Pronóstico.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / genetics*
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Follow-Up Studies
  • Genes, myc / genetics*
  • Humans
  • Immunologic Factors / therapeutic use*
  • In Situ Hybridization, Fluorescence
  • Lymphoma / drug therapy*
  • Lymphoma / genetics
  • Lymphoma / mortality
  • Male
  • Middle Aged
  • Prednisone / therapeutic use
  • Retrospective Studies
  • Rituximab
  • Survival Analysis
  • Translocation, Genetic*
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Biomarkers, Tumor
  • Immunologic Factors
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone